## Hepatitis A Vaccine

### Vaccine Description
- Brands: Havrix® and Vaqta®
- Inactivated whole virus
- Adjuvant: aluminum hydroxide; Vial stopper, syringe cover or syringe plunger may contain latex; See package insert for location and other contents

### Route
- Route: IM (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy)
  Note: Havrix® should not be administered into the gluteal region due to suboptimal response.

### Dose
- Vaqta® (6 months-18 years): 25 units (0.5 mL)
- Havrix® (6 months-18 years): 720 EL.U. (0.5 mL)

### Indications
- All children and adolescents, aged ≥ 1 year
- If aged 6-11 months, dose prior to departing United States plus 2 doses, aged 12-23 months, separated by 6-18 months

### Administration Schedule

<table>
<thead>
<tr>
<th>Dose</th>
<th>Recommended Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Havrix® #1</td>
<td>First dose of either brand at 1 to 18 years</td>
</tr>
<tr>
<td>Vaqta® #1</td>
<td></td>
</tr>
<tr>
<td>Havrix® #2</td>
<td>Havrix®: 6 to 12 months after dose #1</td>
</tr>
<tr>
<td>Vaqta® #2</td>
<td>Vaqta®: 6 to 18 months after dose #1</td>
</tr>
</tbody>
</table>

### Contraindications
- Serious allergic reaction to prior dose or vaccine component
- Moderate or severe acute illness

### Special Considerations
- Consider simultaneous immune globulin administration if person is traveling to highly endemic area sooner than 4 weeks after administration
- Close contact of international adoptee (e.g., household or regular babysitting), within 60 days of arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival)
- You may interchange brands
- DO NOT restart series, no matter how long since previous dose

Additional education may be found at [www.health.mil/hepA](http://www.health.mil/hepA)